Charles River Laboratories Overhauls Leadership with Key CFO and CLO Appointments
Event summary
- Glenn Coleman appointed as Chief Financial Officer, effective April 6, 2026, bringing over 30 years of financial and operational experience in the healthcare sector.
- Kerry Dailey named Chief Legal Officer, effective March 30, 2026, consolidating legal, compliance, communications, government relations, security, and ESG functions under one leader.
- Matthew L. Daniel, current General Counsel, to step down on July 1, 2026, after a 20-year career at Charles River.
- Coleman succeeds Michael G. Knell, who has served as interim CFO since September 2025.
The big picture
Charles River Laboratories is strengthening its leadership team to better position itself in the evolving life sciences industry. The appointments of Glenn Coleman and Kerry Dailey reflect a strategic focus on enhancing financial performance and regulatory compliance, critical for a company that provides essential products and services to pharmaceutical and biotechnology clients. The move underscores the importance of operational excellence and governance in a highly regulated sector.
What we're watching
- Execution Risk
- How Glenn Coleman's strategic financial leadership will impact Charles River's long-term growth and operational excellence.
- Regulatory Compliance
- Whether Kerry Dailey's consolidation of legal and compliance functions will enhance Charles River's ability to navigate complex regulatory environments.
- Governance Dynamics
- The pace at which the new leadership team can drive transformational strategies and maintain disciplined capital deployment, including M&A.
Related topics